Back to top
more

Amylyx Pharmaceuticals (AMLX)

(Real Time Quote from BATS)

$1.91 USD

1.91
308,920

-0.06 (-3.05%)

Updated Jul 29, 2024 01:26 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 39% (97 out of 251)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for AMLX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Amylyx Pharmaceuticals, Inc. [AMLX]

Reports for Purchase

Showing records 1 - 20 ( 31 total )

Company: Amylyx Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 1

06/28/2024

Daily Note

Pages: 5

Neurofilament Wins the Biomarker Debate for ALS

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: Amylyx Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 2

06/24/2024

Daily Note

Pages: 4

Phase 2 Validated Avexitide Open Opportunities in Metabolic Disorder Space

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: Amylyx Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 3

05/10/2024

Company Report

Pages: 7

Calpain is a Well Validated Target for ALS and other Neurodegenerative Diseases

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Amylyx Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 4

04/11/2024

Daily Note

Pages: 4

Interim HELIOS Data Encouraging, Supports C-Peptide as a Surrogate Endpoint in Wolfram

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: Amylyx Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 5

04/08/2024

Company Report

Pages: 4

Positive Biomarker Data from HELIOS has the Potential to Restore Confidence in AMX0035

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: Amylyx Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 6

03/12/2024

Company Report

Pages: 7

From the Ashes of Phoenix a New Focus Rises in Wolfram Syndrome and PSP; Reiterate Buy and PT Down to $8

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Amylyx Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 7

02/23/2024

Company Report

Pages: 7

Investment in Developing ALS Biomarker Panel Important for Company?s Dominance in the ALS Space

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Amylyx Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 8

11/21/2023

Company Report

Pages: 6

Optimized Entry and Exit Levels for AMLX 112123

Provider: Stock Traders Daily

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: Amylyx Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 9

11/10/2023

Company Report

Pages: 7

Relyvrio Discontinuation Rate at Par or Better Than Competitors; Reiterate Buy and PT Down to $42

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: Amylyx Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 10

10/16/2023

Daily Note

Pages: 4

Negative Opinion on AMX0035 Shows Challenges with CHMP?s Assessment of Neurology Disease Trials

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 5.00

Research Provided by a Third Party

Company: Amylyx Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 11

10/06/2023

Company Report

Pages: 7

Acces Compassionnel Coupled with Real World Safety Data Encouraging Ahead of CHMP Decision

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: Amylyx Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 12

08/11/2023

Company Report

Pages: 7

Amylyx Has A Stronger Case Over Other Drugs Approved Under CMA; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: Amylyx Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 13

07/27/2023

Company Report

Pages: 5

Tryst with PSP-Our Insights on ORION

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 5.00

Research Provided by a Third Party

Company: Amylyx Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 14

05/31/2023

Daily Note

Pages: 4

Thoughts on the Next Steps Post CHMP?s Regulatory Review

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 5.00

Research Provided by a Third Party

Company: Amylyx Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 15

05/12/2023

Company Report

Pages: 7

Thoughts on AMX0114, An Anti-Sense Oligo Targeting Calpain-2; Reit. Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: Amylyx Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 16

03/31/2023

Industry Report

Pages: 4

Importance of Real World Evidence in Drug Approvals-Insights From AD/PD 2023 Gothenburg

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 5.00

Research Provided by a Third Party

Company: Amylyx Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 17

03/14/2023

Company Report

Pages: 7

Relyvrio Survival Data is Key for Encouraging Launch; Reit. Buy and PT $50

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: Amylyx Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 18

02/15/2023

Daily Note

Pages: 4

Broadening Payer Coverage by 1H23 Might Be the Growth Driver For Relyvrio

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 5.00

Research Provided by a Third Party

Company: Amylyx Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 19

01/30/2023

Industry Report

Pages: 5

A Snapshot of Novel Targets in Parkinson?s Disease

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 5.00

Research Provided by a Third Party

Company: Amylyx Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 20

11/11/2022

Company Report

Pages: 7

Focusing on Calpain-2 As the Launch Continues to Get Underway; Reit Buy and PT $50

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party
// eof